Newsletter

October 15, 2001

Volume IV, Issue 89

Email : info@otcjournal.com
URL : http://www.otcjournal.com

To OTC Journal Members:

ASTRALIS/ Hercules Development (OTC BB: HDVG) APPOINTS DR. JAMES J. LEYDEN, MD, CHAIRMAN OF MEDICAL ADVISORY BOARD

Evidence is more compelling every day that Astralis will indeed become the dream microcap investment we originally anticipated. Today's announcement provides more evidence that this wii be a major breakthrough for Psoriasis sufferers.

Dr. James Leyden, MD was appointed head of the medical advisory board today. According to the press release, Dr. Leyden was instrumental in the development of Accutane, Bactroban, Nizoral, Cleocin, Benzamycin, Benzaclin, and Minocin. Accutane is the commercially successful and extremely expensive treatment for acne.

According to the press release, Dr. Leyden has also served or is presently serving on the boards of many of the nation’s key dermatological committees, including those of the American Academy of Dermatology and the Dermatology Foundation. Dr. Leyden has also served as a consultant to the US Food and Drug Administration and the Federal Trade Commission, and to drug regulation agencies in England, Germany and Austria.

It is becoming highly likely investors will eventually make a substantial return on their investment dollar if Psoraxine turns out to be a truly revolutionary new treatment for Psoriasis.

Today's news is another in a building block in the ongoing process of bringing this revolutionary discovery to the US market. For OTC Journal followers who were ignoring Energy Power two weeks ago at $2.50, this is your wake up call.

One look at the picture provided to us from the eight year Venezuelan study on Psoraxine should answer all your questions. The potential market runs in the billions, and you have the competitive edge with the infromation now.

Here is the complete text of the news release for your review:

FOR IMMEDIATE RELEASE

ASTRALIS APPOINTS DR. JAMES J. LEYDEN, MD, CHAIRMAN OF MEDICAL ADVISORY BOARD

Developer of ACCUTANE signs contract with Astralis to oversee US clinical trials on PSORAXINE

FLORHAM PARK, NJ, October 15, 2001 – Hercules Development Group (OTC BB:HDVG) is pleased to announce that Astralis, the company with which it has executed a definitive merger agreement, has appointed Dr. James J. Leyden, MD as Chairman of the Company’s Medical Advisory Board. In this role, Dr. Leyden will help coordinate clinical trials on Psoraxine according to FDA guidelines. This appointment is effective immediately.

Dr. Leyden is a Professor of Dermatology at the Hospital of the University of Pennsylvania in Philadelphia. He has served or is presently serving on the boards of many of the nation’s key dermatological committees, including those of the American Academy of Dermatology and the Dermatology Foundation. Dr. Leyden has also served as a consultant to the US Food and Drug Administration and the Federal Trade Commission, and to drug regulation agencies in England, Germany and Austria. Dr. Leyden has also been instrumental in the development, testing and commercialization of Accutane, Bactroban, Nizoral, Cleocin, Benzamycin, Benzaclin, Minocin and the use of bicarbonate to control body odor.

“Dr. Leyden’s appointment as Chairman of Astralis’s Medical Advisory Board is a significant development for the Company,” said Mike Ajnsztajn, CEO of Astralis.

Astralis Chairman, Dr. Jose Antonio O’Daly, MD, PhD commented: “With Dr. Leyden we have added a wealth of expertise in the dermatological science industry. His reputation as a leading medical professional in the field of dermatology means we will be able to enroll the top doctors in the country as investigators for Psoraxine during its clinical trials in the US.”

Dr. Leyden stated: “I have the seen the results generated with Psoraxine on patients in Venezuela over the past eight years, and I am looking forward to starting the American clinical trials in the future.”

The first drug to be developed by Astralis, PSORAXINE, has brought about clinical remission of the skin condition known as Psoriasis during clinical trials conducted in Venezuela. The Company has treated 3,000 patients with Psoraxine to-date. Of these, 638 experienced complete remission and 1,000 have experienced between 70% and 90% remission. The primary end point was the reduction of the Psoriasis Area and Severity Index (PASI) before and after treatment with Psoraxine. Overall, 96% of patients have responded positively to Psoraxine, with few adverse effects, although these results were not independently verified.

Psoriasis affects 7 million people in the United States alone, and conservative estimates indicate that up to 3% of the world population also suffer from this condition—as many as 180 million people. Psoriasis results due to an overproduction of skin by blood cells associated with the immune system. These blood cells become confused and act as though the skin was damaged, manufacturing skin cells at a much faster rate than is required by undamaged skin. This overproduction of skin can cause everything from itchy rash-like patches to painful pustules and massive inflammation. Most current treatments are sub-optimal and some systematic treatments can cause serious side effects. In fact, of the 7 million people living with Psoriasis in the US today, only 1.6 million choose treatment.

Astralis is the developer of Psoraxine, a drug that has brought about a clinical remission of the skin condition Psoriasis in patient trials. The Company has applied for patent protection for composition of matter, method of use, DNA sequence of peptides, and the new gene sequence that fuels Psoraxine. The company is in the process of submitting the IND for FDA approval to start US clinical trials

-30-

FOR MORE INFORMATION CONTACT:
The Investor Relations Group
Peter Waal
1-800-689-2966

Charts Provided Courtesy Of TradePortal.com

The OTC Journal is a proud partner of the SwingWire.com Online Investment Community. A next generation Online Analyst Exchange providing Members the ability to search, review, track and monitor some of the Internet's best Online CAs (CyberAnalysts). Members have the opportunity to potentially achieve higher returns by viewing top performing portfolios and receiving real-time alerts from favorite CAs.

SwingWire.com also has a lucrative incentive model for experienced investors and traders who consistently outperform the market. Share market ideas with other like-minded investors, establish a proven track record, provide insightful commentary, attract followers and ultimately become one of the Internet's highest paid and most sought after CyberAnalysts!

Click here to receive your FREE 30-Day Trial Membership with no further obligation. Sign Up Today!

Disclaimer

The OTCjournal.com Newsletter is an independent electronic publication committed to providing our readers with factual information on selected publicly traded companies. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward maximizing the upside potential for investors while minimizing the downside risk, whenever possible. Moreover, as detailed below, this publication accepts compensation from certain of the companies which it features. Likewise, this newsletter is owned by MarketByte, LLC. To the degrees enumerated herein, this newsletter should not be regarded as an independent publication.

Click Here to view our compensation on every company we have ever covered, or visit the following web address: http://www.otcjournal.com/disclaimer.html for our full profiles and http://www.otcjournal.com/trading-alerts/disclaimer.html for Trading Alerts. MarketByte LLC has been paid a fee of $100,000 in cash and 100,000 options exercisable at $2.50 by the Investor Relations Group for publishing information on Astralis LLC for a period of one year. Fifty thousand options are exercisable immediately, and fifty thousand become eligible on April 1, 2002. Please review our policy on selling shares found within our Mission Statement at our home page.

All statements and expressions are the sole opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the newsletter is neither an offer nor solicitation to buy or sell any securities mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.

The editor, members of the editor's family, and/or entities with which they are affiliated, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication.

The profiles, critiques, and other editorial content of the OTCjournal.com may contain forward-looking statements relating to the expected capabilities of the companies mentioned herein.

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN CONSENT OF THE EDITORS OF OTCjournal.com.

We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission ("SEC") at http://www.sec.govand/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at http://www.sec.gov/consumer/cyberfr.htm. Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.

You can unsubscribe from this list at any time by Clicking Here and HITTING SEND. If you are having difficulty removing yourself or wish to change your address please go to http://listserv.otcjournal.com/opt.cgi?.